source
- Versa Vascular appoints former Medtronic heart franchise leader Bill Shields as CEOBill Shields, who spent 15 years leading Medtronic’s structural heart franchise, is leaving the medtech giant to become chief executive of Versa Vascular, a startup developing tricuspid valve repai…
- Braveheart Bio raises $382.5M in IPO to fund phase 3 trial of cardiac drugBraveheart Bio, a San Francisco biotech, completed an IPO that raised $382.5 million, exceeding its original target. The company increased the share count to 21.2 million and set the price at $18…